

George Apostol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11827809/publications.pdf>

Version: 2024-02-01

10
papers

797
citations

933447

10
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

1099
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 280-299.	46.4	247
2	Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. <i>Science Translational Medicine</i> , 2016, 8, 321ra5.	12.4	210
3	Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. <i>Journal of Neurodevelopmental Disorders</i> , 2016, 8, 1.	3.1	69
4	Divalproex Extendedâ€Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Study. <i>Headache</i> , 2008, 48, 1012-1025.	3.9	59
5	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Î±4Î²2 Agonist ABT-894 in Adults with ADHD. <i>Neuropsychopharmacology</i> , 2013, 38, 405-413.	5.4	48
6	Efficacy and safety of the novel Î±4Î²2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. <i>Psychopharmacology</i> , 2012, 219, 715-725.	3.1	47
7	Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011, 50, 73-84.e1.	0.5	34
8	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. <i>Scientific Reports</i> , 2018, 8, 16970.	3.3	33
9	Divalproex Sodium Extendedâ€Release for the Prophylaxis of Migraine Headache in Adolescents: Results of a Standâ€Alone, Longâ€Term Openâ€Label Safety Study. <i>Headache</i> , 2009, 49, 45-53.	3.9	32
10	Safety and Tolerability of Divalproex Sodium Extendedâ€Release in the Prophylaxis of Migraine Headaches: Results of an Openâ€Label Extension Trial in Adolescents. <i>Headache</i> , 2009, 49, 36-44.	3.9	18